ID: ALA5269963

Max Phase: Preclinical

Molecular Formula: C26H31F3N6O2

Molecular Weight: 516.57

Representations

Canonical SMILES:  CCCn1c(=O)c(C2CCN(C(C)=O)CC2)cc2c(N[C@H](C)c3cc(N)cc(C(F)(F)F)c3)ncnc21

Standard InChI:  InChI=1S/C26H31F3N6O2/c1-4-7-35-24-22(13-21(25(35)37)17-5-8-34(9-6-17)16(3)36)23(31-14-32-24)33-15(2)18-10-19(26(27,28)29)12-20(30)11-18/h10-15,17H,4-9,30H2,1-3H3,(H,31,32,33)/t15-/m1/s1

Standard InChI Key:  QHJORKHOXGOXPD-OAHLLOKOSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 516.57

Molecular Weight (Monoisotopic): 516.2461

AlogP: 4.70

#Rotatable Bonds: 6

Polar Surface Area: 106.14

Molecular Species: NEUTRAL

HBA: 7

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 8

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 3.33

CX LogP: 2.87

CX LogD: 2.87

Aromatic Rings: 3

Heavy Atoms: 37

QED Weighted: 0.46

Np Likeness Score: -1.19

References

1. Liu M, Zhou G, Su W, Gu Y, Gao M, Wang K, Huo R, Li Y, Zhou Z, Chen K, Zheng M, Zhang S, Xu T..  (2023)  Design, Synthesis, and Bioevaluation of Pyrido[2,3-d]pyrimidin-7-ones as Potent SOS1 Inhibitors.,  14  (2.0): [PMID:36793426] [10.1021/acsmedchemlett.2c00490]

Source

Source(1):

• Scientific Literature